Trubion Pharmaceuticals, Inc.company was founded in 1999 and is headquartered in Seattle, Washington. Trubion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases and cancer. The company, in a collaboration with Wyeth, is conducting a phase IIb clinical trial for its lead product candidate, TRU-015, for the treatment of rheumatoid arthritis. The company also offers TRU-016, a phase II/II clinical evaluation product and a novel CD37-targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and certain autoimmune and inflammatory disease indications. It also has collaboration agreement with Wyeth for the development and commercialization of SBI-087 for the treatment of rheumatoid arthritis and SBI-087 for the treatment of systemic lupus erythematosus, as well as other therapeutics directed to CD20, an antigen that is a validated clinical target present on B cells.

Medicis Pharmaceutical Corporation was founded in 1987 and is headquartered in Scottsdale, Arizona. Medicis Pharmaceutical Corporation operates as a specialty pharmaceutical company in the United States and Canada. It develops and markets products for the treatment of dermatological, aesthetic, and podiatric conditions. The company's products address various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis, and cosmesis. Its products include DYNACIN for the treatment of acne and acne-related dermatological conditions; PLEXION, a cleanser product; SOLODYN for the treatment of inflammatory lesions; TRIAZ, a benzoyl peroxide pad for the topical treatment of acne vulgaris; and ZIANA, a gel used on the skin for treatment of acne in patients 12 and older.Medicis Pharmaceutical also offers LOPROX, a shampoo; PERLANE and RESTYLANE for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds; and VANOS, a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. In addition, Medicis Pharmaceutical provides non-dermatological products, including AMMONUL for treating hepatic encephalopathies; and BUPHENYL for the treatment of urea cycle disorder. The company sells its products primarily to wholesale pharmaceutical distributors and retail pharmacy chains. It has a joint development agreement with IMPAX Laboratories, Inc. to develop of five strategic dermatology product opportunities, including an advanced-form SOLODYN product; a strategic alliance with AAIPharma, Inc. for the development, commercialization, and license of a key dermatologic product, SOLODYN; and a strategic collaboration with Hyperion Therapeutics, Inc. for the research and development of a compound referred to as GT4P for the treatment of urea cycle disorder and hepatic encephalopathies.

Cerep offers tools and knowledge to help those companies discover and develop new drugs without having to start from scratch. It also developed a library of compounds that includes promising substances and drug candidates developed with Bristol-Myers Squibb and Sanofi-Aventis. Customers use Cerep's expertise in compound profiling, computational chemistry, in vitro and in vivo pharmacology, and pharmacoinformatics to cut to the chase and develop successful drug candidates.

PTC Therapeutics, Inc. company focuses on post-transcriptional control (PTC) of RNA to develop new drugs. Its GEMS (gene expression modulation by small molecules) technology allows the firm to quickly identify compounds that regulate protein synthesis and therefore could control a disease or condition. PTC Therapeutics is looking to discover, develop, and commercialize new therapies for genetic disorders (including muscular dystrophy and cystic fibrosis), cancer, and infectious diseases (especially hepatitis C).

Guerbet Group is one of Europe's leading makers of contrast agents used in medical imaging. Most of the company's products, such as Xenetix, Hexabrix, and Dotarem, are substances that are injected into the body to make internal organs visible during X-ray and magnetic resonance imaging (MRI) examinations. Subsidiary Simafex manufactures specialty chemicals for use in pharmaceuticals. Guerbet has operations in some 15 countries and is targeting growth in the US. Marcel Guerbet, grandfather of chairman Michel Guerbet, developed the first iodinated contrast agent around the turn of the century; his descendants control the company.

Roche NimbleGen, founded in 1999, serves clients such as academic institutions, government laboratories, and pharmaceutical companies. It is a part of Roche Diagnostics. Roche NimbleGen displays agility in testing DNA. Formerly NimbleGen Systems, the company develops products and services for the analysis of genomes, which include the complete genetic material of an organism. The company produces high-density arrays of long oligo probes offering the deep high quality information necessary to study genomic variation base on ist proprietary Maskless Array Sythesis technology. By understanding the nature and function of genomes, scientists are able to improve a variety of medical and agricultural products.

Stellar Pharmaceuticals Inc. company was founded in 1978 and is based in London, Canada. Stellar Pharmaceuticals Inc. engages in the development and marketing of polysaccharide-based therapeutic products used in the treatment of osteoarthritis and cystitis. It offers NeoVisc, a three injection sodium hyaluronate therapy for the treatment of osteoarthritis; and Uracyst for the treatment of interstitial cystitis, a painful bladder syndrome an inflammatory disease of the urinary bladder wall. The company also has in-licensing agreement for the distribution and sale of BladderChek, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. Stellar markets its products to medical physicians, pharmacies, hospitals, and patient support groups in Canada through its sales force, as well as out-licenses its products to companies in the United States, Europe, Romania, the Russian Federation, China, Israel, the Middle East, Latin America, the Caribbean, Malaysia, Singapore, and Brunei.

NicOx S.A. company researches nitric oxide-donating drugs for the treatment of cardiovascular and metabolic ailments, inflammation, and pain. NicOx is researching the combination of nitric oxide with various compounds to treat a variety of diseases, including osteoarthritis, atherosclerosis (vascular inflammation), hypertension, ophthalmic conditions, and respiratory diseases. Its drug development efforts are partially conducted through co-development and licensing agreements with larger drug companies.

Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, which is in Phase I/II clinical studies is a chimeric monoclonal antibody that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I clinical study, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; and PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases. Facet Biotech Corporation has a collaboration agreement with Biogen Idec Inc. The company is headquartered in Redwood City, California.

meros Corporation was founded in 1994 and is based in Seattle, Washington. Omeros Corporation is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company’s clinically advanced product candidates are derived from its PharmacoSurgerytm platform designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Its PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.